Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/05/033485
CTRI/2021/05/033485
Not yet recruiting
Phase 4

Comparison of Two Treatment Modalities and Role of SIRT3 & SSEA4 as Critical Regulators at the Cross-Roads between Oral Submucous Fibrosis (OSMF) and Oral Cancer

Maulana Azad Institute of Dental Sciences0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: K135- Oral submucous fibrosis

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: K135- Oral submucous fibrosis
Sponsor
Maulana Azad Institute of Dental Sciences
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Clinically and histopathologically proven cases of OSMF and OSCC. Subjects with prior informed consent.

Exclusion Criteria

  • •Patients who are not willing to participate.
  • •Patients with severe systemic disease.
  • •Pregnant and nursing women.
  • •Subjects with mouth opening less than 15 mm.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy - HMGDMajor depressive disorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOS
EUCTR2008-002319-42-SEEli Lilly and Company Limited1,160
Active, not recruiting
Phase 1
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy - HMGDMajor depressive disorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOS
EUCTR2008-002319-42-SIEli Lilly and Company Limited1,160
Active, not recruiting
Phase 1
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy - HMGD(a)
EUCTR2008-002319-42-FREli Lilly and Company Limited1,160
Active, not recruiting
Not Applicable
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy - HMGD
EUCTR2008-002319-42-DKEli Lilly and Company Limited1,160
Active, not recruiting
Not Applicable
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy - HMGD(a)Major depressive disorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOS
EUCTR2008-002319-42-HUEli Lilly and Company Limited1,160